Deep Breeze's vibration-based pulmonary imaging system:
This article was originally published in Clinica
The US FDA has granted 510(k) marketing clearance for the VRIXP, an imaging system developed by Israeli firm Deep Breeze. The product employs vibration response imaging (VRI) technology, a noninvasive, radiation-free system that uses lung sounds to create dynamic images of the lungs. It records the sounds of the patient's breath, using sensors applied to the back, and then uses an algorithm to convert these data into images. The firm contends that changes in tissue composition or airflow alter the way in which sounds within the lungs vibrate. Or-Akiva-based Deep Breeze plans to launch VRIXP in the US at the 2007 CHEST meeting, to be held in Chicago in October. It received CE mark approval for sale in Europe in September 2005 (see Clinica No 1176, p 19).
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.